ST6GAL1 and cancer: Earlier studies indicated that ST6Gal-I-catalyzed hypersialylation of β1 integrins promoted cancer progression by upregulating cell motility in vitro [13], and that the absence of hypersialylation favored carcinoma differentiation in vivo [53].